Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily S Reese

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|September 14, 2010
Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trialsC Daniel Mullins, Danielle Whicher, Emily S Reese, et al.
Pharmacotherapy|March 31, 2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrelEmily S Reese, C Daniel Mullins, Amber L Beitelshees, et al.
Journal of Comparative Effectiveness Research|May 31, 2023
Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims databaseRamzi Argoubi, Emily S Reese, Martina Furegato, et al.
Cancer Medicine|January 10, 2014
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patientsEmily S Reese, Eberechukwu Onukwugha, Nader Hanna, et al.
Cancer Medicine|January 10, 2014
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patientsZhiyuan Zheng, Nader Hanna, Eberechukwu Onukwugha, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a modelNirupama D Mitikiri, Emily S Reese, Arif Hussain, et al.
Journal of the American College of Surgeons|September 11, 2015
Economic Impact of Alvimopan Considering Varying Definitions of Postoperative IleusStephanie R Earnshaw, Teresa L Kauf, Cheryl McDade, et al.
Future Oncology (London, England)|April 7, 2022
Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safetyZarmina S Khankhel, Sarah Goring, Sarah Bobiak, et al.
Molecular Genetics & Genomic Medicine|November 14, 2025
Living With Hypochondroplasia: A Qualitative Exploration of Children's and Caregivers' Experiences, Challenges, and Unmet NeedsElisabeth M Oehrlein, Reni Pekala, Stacie Cavallaro, et al.
Cancer Medicine|October 20, 2022
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatmentDavid P Cosgrove, Emily S Reese, Nicole M Fulcher, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|September 14, 2010
Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trialsC Daniel Mullins, Danielle Whicher, Emily S Reese, et al.
Pharmacotherapy|March 31, 2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrelEmily S Reese, C Daniel Mullins, Amber L Beitelshees, et al.
Journal of Comparative Effectiveness Research|May 31, 2023
Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims databaseRamzi Argoubi, Emily S Reese, Martina Furegato, et al.
Cancer Medicine|January 10, 2014
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patientsEmily S Reese, Eberechukwu Onukwugha, Nader Hanna, et al.
Cancer Medicine|January 10, 2014
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patientsZhiyuan Zheng, Nader Hanna, Eberechukwu Onukwugha, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a modelNirupama D Mitikiri, Emily S Reese, Arif Hussain, et al.
Journal of the American College of Surgeons|September 11, 2015
Economic Impact of Alvimopan Considering Varying Definitions of Postoperative IleusStephanie R Earnshaw, Teresa L Kauf, Cheryl McDade, et al.
Future Oncology (London, England)|April 7, 2022
Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safetyZarmina S Khankhel, Sarah Goring, Sarah Bobiak, et al.
Molecular Genetics & Genomic Medicine|November 14, 2025
Living With Hypochondroplasia: A Qualitative Exploration of Children's and Caregivers' Experiences, Challenges, and Unmet NeedsElisabeth M Oehrlein, Reni Pekala, Stacie Cavallaro, et al.
Cancer Medicine|October 20, 2022
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatmentDavid P Cosgrove, Emily S Reese, Nicole M Fulcher, et al.
Pageof 2